Search results for "Flutamide"

showing 10 items of 18 documents

Treatment of hyperandrogenic alopecia in women

2003

Many women with androgenic alopecia have normal circulating androgen levels. Increased scalp sensitivity to androgens may account for these cases. Even when androgen levels are increased, no particular pattern has emerged. Classical anti-androgen measures have proved disappointing, in contrast to the results obtained in women with hirsutism or acne. This study evaluated flutamide and finasteride in 36 premenopausal, hyperandrogenic women presenting with androgenic alopecia. Frontal hair thinning was assessed in photos of the frontoparietal region using the Ludwig grading system. Thirty ovulatory women matched for age and body weight served as a control group. Groups of 12 subjects received …

Adultmedicine.medical_specialtyRandomizationmedicine.drug_classDehydroepiandrosteroneEthinyl EstradiolAntiandrogenFlutamidelaw.inventionchemistry.chemical_compound5-alpha Reductase InhibitorsRandomized controlled triallawInternal medicineHumansMedicineTestosteroneEnzyme InhibitorsCyproterone AcetateTestosteronehirsutismGynecologyDehydroepiandrosterone Sulfatebusiness.industryFinasterideHyperandrogenismObstetrics and GynecologyCyproterone acetateAlopeciaAndrogen AntagonistsGeneral MedicineAndrogenmedicine.diseaseFlutamideRegimenEndocrinologyHair lossItalyLiverReproductive MedicinechemistryFinasterideCyproteroneFemaleHyperandrogenismbusinessmedicine.drugFertility and Sterility
researchProduct

Testosterone and oxidative stress: the oxidation handicap hypothesis

2007

Secondary sexual traits (SST) are usually thought to have evolved as honest signals of individual quality during mate choice. Honesty of SST is guaranteed by the cost of producing/maintaining them. In males, the expression of many SST is testosterone-dependent. The immunocompetence handicap hypothesis has been proposed as a possible mechanism ensuring honesty of SST on the basis that testosterone, in addition to its effect on sexual signals, also has an immunosuppressive effect. The immunocompetence handicap hypothesis has received mixed support. However, the cost of testosterone-based signalling is not limited to immunosuppression and might involve other physiological functions such as the…

Male0106 biological sciencesErythrocytes[ SDV.IMM.IA ] Life Sciences [q-bio]/Immunology/Adaptive immunology[ SDV.BA ] Life Sciences [q-bio]/Animal biologymedicine.disease_cause01 natural sciencesFlutamidechemistry.chemical_compoundimmunocompetence handicap hypothesisoxidative stressTestosteronePasseriformesComputingMilieux_MISCELLANEOUSGeneral Environmental Science[SDV.EE]Life Sciences [q-bio]/Ecology environmentImmunity CellularSex Characteristics0303 health sciences[SDV.BA]Life Sciences [q-bio]/Animal biology[SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE]General Medicine[ SDE.MCG ] Environmental Sciences/Global Changes[ SDV.BID.EVO ] Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE][SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunologyMate choiceSexual selectionImmunocompetenceGeneral Agricultural and Biological SciencesResearch ArticleSex characteristics[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]anti-androgenmedicine.medical_specialty[SDE.MCG]Environmental Sciences/Global Changesfree radicals[SDV.BID]Life Sciences [q-bio]/BiodiversityBiology010603 evolutionary biologyGeneral Biochemistry Genetics and Molecular Biology[ SDV.EE ] Life Sciences [q-bio]/Ecology environment03 medical and health sciencesInternal medicinemedicineAnimalsSexual selectiosexual selection[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[ SDV.OT ] Life Sciences [q-bio]/Other [q-bio.OT][ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyZebra finch030304 developmental biology[ SDV.BID ] Life Sciences [q-bio]/Biodiversity[ SDE.BE ] Environmental Sciences/Biodiversity and EcologyGeneral Immunology and Microbiology[SDV.OT] Life Sciences [q-bio]/Other [q-bio.OT]Testosterone (patch)[SDE.ES]Environmental Sciences/Environmental and SocietyFlutamideevolutionary trade-offsOxidative stressnEndocrinologychemistry[SDE.BE]Environmental Sciences/Biodiversity and Ecology[ SDE.ES ] Environmental Sciences/Environmental and SocietyOxidative stressProceedings of the Royal Society B: Biological Sciences
researchProduct

Fluorinated and pegylated polyaspartamide derivatives to increase solubility and efficacy of Flutamide

2012

New fluorinated amphiphilic copolymers based on a biocompatible polyaspartamide have been prepared in order to obtain polymeric micelles useful for delivering anticancer drugs. In particular, α,β-poly(N-2-hydroxyethyl)-d,l-aspartamide (PHEA) has been derivatized with polyethylene glycol (PEG(2000)) and ethylendiamine (EDA). Both these portions form the hydrophilic part of the copolymer, while the hydrophobic moiety is given by 1,2,4-oxadiazoles: 5-pentafluorophenyl-3-perfluoroheptyl-1,2,4-oxadiazole (PPOX) or 3-carboxyethyl-5-pentadecafluoroheptyl-1,2,4-oxadiazole (CPOX). Copolymers named PHEA-PEG(2000)-EDA-PPOX and PHEA-PEG(2000)-EDA-CPOX have been prepared with various degrees of derivati…

MaleAntineoplastic Agents HormonalPolymersSize-exclusion chromatographyPharmaceutical SciencePolyethylene glycolAdenocarcinomaPolyethylene Glycolschemistry.chemical_compoundDrug Delivery SystemsCell Line TumorPolymer chemistryCopolymerHumansSolubilityDerivatizationMicellesCell Proliferationchemistry.chemical_classificationDrug CarriersOxadiazolesProstatic NeoplasmsDihydrotestosteroneSettore CHIM/06 - Chimica OrganicaPolymerEthylenediaminesFlutamideCancer targeting cell model colloidal particles drug delivery polymerSolubilitychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryChromatography GelMicroscopy Electron ScanningPyrenePeptidesHydrophobic and Hydrophilic InteractionsJournal of Drug Targeting
researchProduct

Polymeric Nanocarriers for Magnetic Targeted Drug Delivery: Preparation, Characterization, and in Vitro and in Vivo Evaluation

2013

In this paper the preparation of magnetic nano- carriers (MNCs), containing superparamagnetic domains, is reported, useful as potential magnetically targeted drug delivery systems. The preparation of MNCs was performed by using the PHEA-IB-p(BMA) graft copolymer as coating material through the homogenization−solvent evaporation method. Magnetic and nonmagnetic nanocarriers containing flutamide (FLU-MNCs) were prepared. The prepared nanocarriers have been exhaustively characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM), and magnetic measurements. Biological evaluation was performed by in vitro cytotoxicity and cell uptake tests and in vivo biodistribution …

MaleMaterials sciencePharmaceutical ScienceAntineoplastic AgentsNanotechnologyMagneticsDrug Delivery SystemsDynamic light scatteringIn vivoCell Line TumorDrug DiscoveryLNCaPAnimalsHumansDistribution (pharmacology)Tissue DistributionParticle SizeRats WistarMagnetite NanoparticlesDrug Carriersequipment and suppliesmagnetic nanocarrier magnetic targeting flutamide superparamagnetic nanoparticlesFlutamideIn vitroRatsTargeted drug deliverySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBiophysicsMolecular MedicineNanocarriersPeptideshuman activitiesSuperparamagnetismMolecular Pharmaceutics
researchProduct

Antiandrogens alone or in combination for treatment of prostate cancer: The European experience

1989

Abstract In Europe, antiandrogens have been used for many years to treat prostate cancer, either as monotherapy or as part of a “combination therapy” with either surgical or chemical castration. However, considerable debate still exists regarding the relative benefits of combination therapy versus antiandrogen monotherapy or castration alone. This article reviews the European experience with antiandrogen therapy, including the personal experiences of the authors.

MaleOncologymedicine.medical_specialtyCombination therapyAntiandrogensmedicine.drug_classUrologyurologic and male genital diseasesAntiandrogenchemistry.chemical_compoundProstate cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineAntiandrogen TherapyChemical castrationRandomized Controlled Trials as TopicGynecologybusiness.industryProstatic NeoplasmsAndrogen Antagonistsmedicine.diseaseCombined Modality TherapyFlutamideEuropeCastrationchemistrybusinessOrchiectomyhormones hormone substitutes and hormone antagonistsUrology
researchProduct

INULIN BASED HYDROGEL FOR ORAL DELIVERY OF FLUTAMIDE: PREPARATION, CHARACTERIZATION AND IN VIVO RELEASE STUDIES

2012

The ability of a hydrogel obtained by crosslinking INUDV and PEGBa to facilitate sustained release of flutamide is examined. The hydrogel is prepared in pH = 7.4 PBS and no toxic solvents or catalysts are used. It is recovered in microparticulate form and its size distribution is determined. Mucoadhesive properties are evaluated in vitro by reproducing gastrointestinal conditions. Flutamide is loaded into the hydrogel using a post-fabrication encapsulation procedure that allows a drug loading comparable to that of market tablets. Drug-loaded microparticles are orally administered to cross-bred dogs and the in vivo study demonstrates their ability to prolong the half-life of the principal ac…

MalePolymers and PlasticsInulinAdministration OralBiological AvailabilityBioengineeringPharmacologyFlutamideBiomaterialschemistry.chemical_compoundDogsDrug Delivery SystemsIn vivoMaterials ChemistryDistribution (pharmacology)AnimalsHypoglycemic AgentsInsulinActive metabolitetechnology industry and agricultureAndrogen AntagonistsHydrogelsIn vitroFlutamideBioavailabilitychemistrySelf-healing hydrogelsBiotechnologyHalf-Life
researchProduct

Androgen receptors and hormone sensitivity of a human prostatic cancer cell line (PC-3) are modulated by natural beta-interferon.

1994

Androgen receptors are expressed at a low level in the cell line PC-3, which does not respond to either androgens or antiandrogens. If these cells are exposed to natural beta-interferon (beta-IFN) a reduction in cell growth and an increase in androgen receptors, evaluated by both biochemical and immunocytochemical techniques, occur. This increase seems not to be related to a selective block of PC-3 in any phase of the cell cycle. Pretreatment with beta-IFN determines in PC-3 cells a partial responsiveness to the androgen dihydrotestosterone as reflected by the increase in cell number. Moreover, the antiandrogen hydroxyflutamide shows agonistic properties by increasing the cell number of PC-…

Malemedicine.medical_specialtymedicine.drug_classUrologyDrug Resistanceurologic and male genital diseasesAntiandrogenchemistry.chemical_compoundInternal medicinemedicineTumor Cells CulturedHumansCell growthCell CycleProstatic NeoplasmsAndrogen AntagonistsDihydrotestosteroneInterferon-betaCell cycleAndrogenImmunohistochemistryFlutamideAndrogen receptorEndocrinologychemistryCell cultureReceptors AndrogenDihydrotestosteroneAndrogensHydroxyflutamideCell Divisionmedicine.drugUrological research
researchProduct

Design, synthesis, and biological evaluation of nonsteroidal cycloalkane[d]isoxazole-containing androgen receptor modulators.

2012

We report here the design, preparation, and systematic evaluation of a novel cycloalkane[d]isoxazole pharmacophoric fragment-containing androgen receptor (AR) modulators. Cycloalkane[d]isoxazoles form new core structures that interact with the hydrophobic region of the AR ligand-binding domain. To systematize and rationalize the structure-activity relationship of the new fragment, we used molecular modeling to design a molecular library containing over 40 cycloalkane[d]isoxazole derivatives. The most potent compound, 4-(3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazol-3-yl)-2-(trifluoromethyl)benzonitrile (6a), exhibits antiandrogenic activity significantly greater than that of the most widely used …

Models MolecularBicalutamideMolecular modelStereochemistryProtein ConformationChemistry Techniques Syntheticchemistry.chemical_compoundStructure-Activity RelationshipDrug DiscoveryChlorocebus aethiopsmedicineAnimalsIsoxazoleNonsteroidal Anti-AndrogensTrifluoromethylta1182CycloparaffinsIsoxazolesAndrogen receptorCycloalkaneBenzonitrilechemistryReceptors AndrogenDrug DesignCOS CellsMolecular MedicineHydroxyflutamidemedicine.drugJournal of medicinal chemistry
researchProduct

Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens.

1990

Our preliminary experience shows that flutamide is effective in patients with stage C or D prostate cancer. Local and distant response rates are comparable to those obtained with "classic" hormone therapy. Libido and sexual potency generally are unaffected. Palliation of symptoms, which is frequent, is usually accompanied by improved performance status and quality of life. Side effects are slight or moderate, but elevated transaminase levels in patients with borderline liver insufficiency are possible.

OncologyMalemedicine.medical_specialtyAntiandrogensmedicine.medical_treatmentUrologyImidazolidinesGeneral Biochemistry Genetics and Molecular BiologyFlutamideProstate cancerchemistry.chemical_compoundHistory and Philosophy of ScienceProstateInternal medicinemedicineCarcinomaHumansLibidobusiness.industryGeneral NeuroscienceCarcinomaImidazolesProstatic NeoplasmsAndrogen Antagonistsmedicine.diseaseFlutamidemedicine.anatomical_structurechemistryElevated transaminasesHormone therapybusinessAnnals of the New York Academy of Sciences
researchProduct

Re: Does Oral Antiandrogen Use Before Leuteinizing Hormone-Releasing Therapy in Patients with Metastatic Prostate Cancer Prevent Clinical Consequence…

2010

Oh et al report their experience with 1566 metastatic prostate cancer patients treated with luteinising hormone-releasing hormone (LHRH) agonists in the area of Boston, Massachusetts, USA. Of these patients, 79.5% were given antiandrogens (bicalutamide, flutamide, or nilutamide) before the first LHRH agonist dose. The remaining patients (20.5%) did not receive antiandrogens. In all patients, complications appearing within 30 d and attributable to a flare phenomenon (fractures, spinal cord compression, bladder outlet obstruction, exacerbation of pain) were assessed retrospectively. Such complications were extremely rare ( or =7 d before starting the LHRH analogues) made no difference.The aut…

Oncologymedicine.medical_specialtyBicalutamideAntiandrogensmedicine.drug_classbusiness.industryUrologyUrologyurologic and male genital diseasesAntiandrogenmedicine.diseaseFlutamidechemistry.chemical_compoundProstate cancerchemistryInternal medicineNilutamidemedicineAntiandrogen Therapybusinesshormones hormone substitutes and hormone antagonistsLeuteinizing hormonemedicine.drugEuropean Urology
researchProduct